12.3 Platelet Cyclic GMP Levels and the Aggregating Response to Adrenaline in Essential Hypertensive patients
- PDF / 52,043 Bytes
- 1 Pages / 592.441 x 751.181 pts Page_size
- 50 Downloads / 188 Views
High Blood Press Cardiovasc Prev 2008; 15 (3): 171-215 1120-9879/08/0003-0171/$48.00/0 © 2008 Adis Data Information BV. All rights reserved.
Vessels and Endothelium 12.3 Platelet Cyclic GMP Levels and the Aggregating Response to Adrenaline in Essential Hypertensive patients C. Sala (1), M. Rescaldani (1), A. Morganti (2) ` di Milano, Istituto di Medicina Cardiovascolare, Fondazione (1)Universita ` di Milano, Istituto di Medicina Policlinico IRCCS, Milano; (2)Universita Cardiovascolare, Milano, Italy Introduction. A variable in vitro aggregating response to adrenaline (A) has been described in human platelets. Nitric oxide inhibits platelet aggregation via the second messenger cyclic GMP (cGMP). In essential hypertensive patients (EH) we tested whether platelet aggregation to A is affected by intraplatelet levels of cGMP. Methods. From 39 untreated, grade I-II, supine EH (age 44±2 yr, M/F 30/9, smoke y/n 12/27, BP 141/ 92±3/2 mmHg, HR 75±2 bt/min) peripheral venous blood was sampled for platelet cGMP (RIA on acid extracts of washed platelets) and for platelet aggregation to A (final concentration 20, 10, 5, 2.5 μM, turbidimetric method on platelet rich plasma, PRP); aggregation was tested at time 0 and after 60 minutes of PRP incubation at room temperature. Data are expressed as means±sem. Results. At time 0, the dose-response curve of platelet aggregation to A was blunted in 16 EH (hyporesponders) compared to 23 normo-responders (215±25 vs 2617±248 auc, arbitrary units, p
Data Loading...
